Journal article
Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial
Abstract
BACKGROUND. Abdominal obesity, characterized by ectopic fat deposition in skeletal muscle and liver tissue, has been associated with insulin resistance and increased risk for type 2 diabetes mellitus. The aim of this study was to evaluate whether treatment with the angiotensin II type 1 (AT-1) receptor blocker telmisartan can reduce intramyocellular lipid (IMCL) and hepatic fat storage, thereby improving insulin sensitivity among individuals …
Authors
Chetty VT; Damjanovic S; Gerstein H; Singh N; Yusuf S; Anand SS; Sharma AM
Journal
Blood Pressure, Vol. 23, No. 1, pp. 54–60
Publisher
Taylor & Francis
Publication Date
February 1, 2014
DOI
10.3109/08037051.2013.791411
ISSN
0803-7051